T
AUPH icon

Tidemark’s Aurinia Pharmaceuticals AUPH Stock Holding History

Tidemark’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.7K Hold
4,340
– – 0.02% 258
2026
Q1 		$64.3K Hold
4,340
– – 0.02% 238
2025
Q4 		$69.2K Hold
4,340
– – 0.02% 209
2025
Q3 		$48K Hold
4,340
– – 0.01% 250
2025
Q2 		$36.8K Hold
4,340
– – 0.01% 280
2025
Q1 		$34.9K Hold
4,340
– – 0.01% 287
2024
Q4 		$39K Hold
4,340
– – 0.01% 273
2024
Q3 		$31.8K Hold
4,340
– – 0.01% 289
2024
Q2 		$24.8K Hold
4,340
– – 0.01% 298
2024
Q1 		$21.7K Hold
4,340
– – 0.01% 323
2023
Q4 		$39K Buy
+4,340
New +$35.7K 0.02% 259

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tidemark's AUPH Position: Q2 2026 in Review

Tidemark held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 4,340 shares worth $73.7K. The position accounts for 0.02% of the portfolio, ranked #258.

Tidemark first reported a position in AUPH in Q4 2023 and has held it in 11 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Tidemark held 4,340 shares of Aurinia Pharmaceuticals worth $73.7K as of Q2 2026.
  • Tidemark left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up 0.02% of Tidemark's portfolio in Q2 2026, its #258 holding.
  • Tidemark first reported a position in Aurinia Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.